Clinical trials: Platinum-sensitive Ovarian Cancer
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL2 (NCT01891344)
- Testing
- Oral rucaparib
- Where
- 75 sites in United States, Australia and 4 more
- Volunteers
- 491 people
- Sponsor
- pharmaand GmbH
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at…
- Trial name
- SOLO3 (NCT02282020)
- Testing
- OLAPARIB, Single agent chemotherapy
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
Ovarian Cancer Recurrent
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes in women with FIGO stage III and IV epithelial…
- Trial name
- NCT03657966
- Testing
- DCVAC/OvCa, Standard of Care Chemotherapy
- Where
- 8 sites in Czechia
- Volunteers
- 33 people
- Sponsor
- SOTIO a.s.
Platinum Sensitive, BRCA Mutated
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with…
- Conditions
- Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
- Trial name
- NCT01874353
- Testing
- Olaparib 300mg tablets
- Where
- 126 sites in United States, Australia and 15 more
- Volunteers
- 327 people
- Sponsor
- AstraZeneca
Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and…
- Trial name
- NCT01847274
- Testing
- Active comparator: Niraparib
- Where
- 112 sites in United States, Austria and 13 more
- Volunteers
- 596 people
- Sponsor
- Tesaro, Inc.
Ovarian Cancer, Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL3 (NCT01968213)
- Testing
- Rucaparib
- Where
- 96 sites in United States, Australia and 9 more
- Volunteers
- 564 people
- Sponsor
- pharmaand GmbH
Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
The purpose of this study is to compare progression-free survival in patients with advanced ovarian cancer treated with ZD4054 in combination with carboplatin+paclitaxel versus placebo in combination with carboplatin+paclitaxel.
- Trial name
- NCT00929162
- Testing
- ZD4054 Zibotentan, Paclitaxel, Carboplatin
- Where
- 20 sites in Germany, Italy
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Ovarian Cancer
A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients
To evaluate the efficacy, safety tolerability of maintenance therapy with Fluzoparib(A PARP inhibitor) versus placebo in Chinese patients with recurrent ovarian cancer who achieved a complete response (CR) or partial response…
- Trial name
- NCT03863860
- Testing
- Fluzoparib capsules
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Ovarian Cancer, Ovarian Cancer Recurrent
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer.
- Trial name
- MAIA-ovarian (NCT06888921)
- Testing
- COM701, Normal Saline
- Where
- 27 sites in United States, France and 1 more
- Volunteers
- 60 people
- Sponsor
- Compugen Ltd
Fallopian Tube Cancer, Primary Peritoneal Cancer
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
The primary purpose of the study is to evaluate the efficacy of R-DXd with or without bevacizumab as maintenance therapy compared with standard of care (SOC) in participants with platinum-sensitive ovarian cancer (PSOC) as…
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
- Trial name
- NCT07791732
- Testing
- R-DXd, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- Daiichi Sankyo
Ovarian Cancer
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy
- Trial name
- NCT00753545
- Testing
- AZD2281
- Where
- 107 sites in United States, Australia and 15 more
- Volunteers
- 265 people
- Sponsor
- AstraZeneca
Ovarian Neoplasms
A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)
Doxorubicin has been used to treat ovarian cancer as part of different combination therapies, but high cumulative doses should be avoided because of the risk of cardiotoxicity.
- Trial name
- NCT00780039
- Testing
- Pegylated Liposomal Doxorubicin, Carboplatin
- Volunteers
- 58 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR)…
- Trial name
- NCT03519230
- Testing
- Pamiparib capsule
- Where
- 28 sites in China
- Volunteers
- 224 people
- Sponsor
- BeiGene
Recurrent Ovarian Cancer
Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer
The purpose of this randomized clinical study is to confirm the utility of chemosensitivity (ChemoID) tumor testing on cancer stem cells as a predictor of clinical response in recurrent epithelial ovarian cancer (EOC), fallopian…
- Trial name
- ACSCO (NCT03632798)
- Testing
- ChemoID assay, Chemotherapy
- Where
- 3 sites in United States
- Sponsor
- Cordgenics, LLC
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.
- Conditions
- Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer
- Trial name
- NCT05335993
- Testing
- Oregovomab, Niraparib
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- CanariaBio Inc.
Ovarian Cancer
Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)
[Objectives] Objectives include following to capture safety and efficacy of LYNPARZA in actual clinical use. 1. ADR development in actual clinical use 2. Factors which may affect safety and efficacy 3.
- Trial name
- NCT03505307
- Volunteers
- 846 people
- Sponsor
- AstraZeneca
Ovarian Neoplasms
ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or…
- Trial name
- NCT00325351
- Testing
- Sagopilone (ZK 219477) + carboplatin
- Where
- 16 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- Bayer
Peritoneal Cancer, Ovarian Cancer
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
This research study was designed to determine the effectiveness of the drug, topotecan, given intravenously (into a vein) together with the drug gemcitabine in patients with recurrent platinum-sensitive ovarian, fallopian or…
- Conditions
- Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
- Trial name
- NCT00061308
- Testing
- Topotecan, Gemcitabine
- Where
- 19 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Platinum-sensitive Relapsed Ovarian Cancer
Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient
This is a 2:1 randomized, double-blind, placebo-controlled, multi-center, phase III clinical study evaluating the efficacy and safety of ZL-2306 (niraparib) for maintenance treatment in patients with platinum-sensitive relapsed…
- Trial name
- NCT03705156
- Testing
- ZL-2306(nirapairb)
- Where
- 27 sites in China
- Volunteers
- 265 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Ovarian Cancer, Peritoneal Carcinomatosis
Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
The purpose of this study is to determine if Olvi-Vec oncolytic immunotherapy is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer and peritoneal carcinomatosis.
- Conditions
- Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
- Trial name
- NCT02759588
- Testing
- Olvi-Vec, Platinum-doublet with or without bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Genelux Corporation